1,850 reports of this reaction
3.1% of all BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE reports
#5 most reported adverse reaction
OVERDOSE is the #5 most commonly reported adverse reaction for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, manufactured by INDIVIOR INC.. There are 1,850 FDA adverse event reports linking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE to OVERDOSE. This represents approximately 3.1% of all 59,605 adverse event reports for this drug.
Patients taking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE who experience overdose should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OVERDOSE is moderately reported among BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to overdose, the following adverse reactions have been reported for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE:
The following drugs have also been linked to overdose in FDA adverse event reports:
OVERDOSE has been reported as an adverse event in 1,850 FDA reports for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OVERDOSE accounts for approximately 3.1% of all adverse event reports for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, making it a notable side effect.
If you experience overdose while taking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.